CD274 and melanoma: Mechanistically, melanoma cells upregulate alternative checkpoint receptors such as TIM−3, LAG−3, and TIGIT, which maintain T−cell exhaustion even after PD−1/PD−L1 or CTLA−4 blockade (80–82).